138356-21-5
138356-21-5 結(jié)構(gòu)式
基本信息
BD1047.2HBr
BD 1047 HBr
BD-1047
BD 1047
BD1047.2HBr(1K/g)
BD 1047 (hydrobromide)
N1-(3,4-DICHLOROPHENETHYL)-N1,N2,N2-TRIMETHYLETHANE-1,2-DIAMINE 2HBR
N1-(3,4-dichlorophenethyl)-N1,N2,N2-trimethylethane-1,2-diamine dihydrobromide
N-[2-(3,4-Dichlorophenyl)ethyl]-N,N',N'-trimethyl-1,2-ethanediamine dihydrobromide
n-[2-(3,4-dichlorophenyl)ethyl]-n,n',n'-trimethylethane-1,2-diamine dihydrobromide
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/08/19 | S0106 | BD-1047鹽酸鹽 BD-1047 dihydrobromide | 138356-21-5 | 5mg | 753.46元 |
| 2024/08/19 | S0106 | BD-1047鹽酸鹽 BD-1047 dihydrobromide | 138356-21-5 | 25mg | 2024.47元 |
常見問題列表
| Target | Value |
|
σ1 receptor
() |
BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.
BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.
BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.
BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).
BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity.
| Animal Model: | Male Albino Swiss mice (50 days old, 25–28 g) |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Decreased the APO-induced climbing at the dose of 10 mg/kg in mice. |